
Did Amazon Just Say "Checkmate" to The Trade Desk?
In recent years, Amazon has been focused on an area that has become the company's fastest-growing business: advertising. What began as a way for Amazon to capitalize on the digital real estate on its website is now getting an increasing amount of attention and resources. In fact, a couple of recent developments have put Amazon on a collision course with The Trade Desk (NASDAQ: TTD), one of the leading names in programmatic advertising.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Did Amazon just say "checkmate" to The Trade Desk? Let's see what the evidence reveals.
Poaching customers?
The Trade Desk is the leading independent provider of programmatic advertising services via its demand-side platform (DSP). This self-serve platform helps advertisers and ad agencies purchase digital advertising space and provides a magnitude of data and analytics to track progress and help manage their ad campaigns. What sets The Trade Desk apart in the digital advertising space is its industry-leading technology and the long-term partnerships it has forged with the world's largest ad agencies.
Furthermore, each of the "walled gardens" -- including Alphabet 's Google, Meta Platforms, and Amazon -- has a vested interest in directing ads to their own sites, creating a clear conflict of interest. The Trade Desk's independence has helped attract new business and fuel its impressive growth streak, as the stock has surged 2,350% since the company's IPO in late 2016.
However, evidence suggests Amazon is doing its level best to poach The Trade Desk's customers. A recent report by Adweek suggested that marketers have been moving millions of dollars in ad spending from The Trade Desk to Amazon. Advertisers have been attracted by cut-rate pricing, the growing reach of Prime Video, and access to the company's exclusive live sports programming, according to the report.
On its own, this normally wouldn't raise an eyebrow, but Amazon recently made another move that suggests the company is coming for The Trade Desk.
An eye-opening partnership
Last month, Amazon announced a strategic partnership with Roku (NASDAQ: ROKU) that will provide advertisers with access to "the largest authenticated connected TV (CTV) footprint in the U.S. exclusively through Amazon DSP," according to the press release. It goes on to note that the pair reaches an estimated 80 million CTV households, representing more than 80% of all CTV households in the country. The partnership includes many of the most popular streaming channels, including ad-supported offerings by most of the major players.
Early results are impressive. Advertisers using this new integration reached 40% more unique viewers with the same budget. Perhaps more importantly, it reduced the number of times a person saw the same ad by almost 30%, solving a common problem in CTV advertising.
Roku's reach in the U.S. is undeniable. The streaming pioneer closed out 2024 with roughly 90 million streaming households and more than 34 billion streaming hours -- which works out to more than four hours of viewing per household per day.
Does this spell trouble for The Trade Desk?
It's important to view these developments in the context of the overall trajectory of the industry. Total ad spending has doubled since 2016 and is expected to climb roughly 9% and surpass $1 trillion in 2025, according to eMarketer. Digital advertising is the fastest-growing segment of the industry, accounting for roughly $764 billion in ad spending this year. The growing market size represents a greater opportunity for all the major adtech players.
Wall Street seems to have mixed feelings about these developments. Analysts at MoffettNathanson believe this shows that Amazon is "chipping away" at The Trade Desk's moat. On the other hand, analysts at Citi cite channel checks in concluding that The Trade Desk is "the clear market share leader" and best-performing DSP. Despite the growing competition, analysts at Evercore ISI posit that Google might actually have more to lose, since more of its business overlaps with that of Amazon.
So, did Amazon just say "checkmate" to The Trade Desk? I would respond with a resounding "no." During the period in which Amazon was reportedly siphoning away "millions" from The Trade Desk, Amazon grew its advertising sales 18% year over year, while The Trade Desk's revenue grew 25%. This helps to illustrate that this isn't a zero-sum game, and there will no doubt be more than one winner.
Furthermore, The Trade Desk recently released its cutting-edge Kokai platform, which integrates artificial intelligence (AI) throughout the ad buying process, providing greater transparency and better outcomes for users.
Given The Trade Desk's industry-leading market share, state-of-the-art technology, and enduring relationships with ad agencies, I would argue that The Trade Desk remains ahead of the game. And, at 34 times next year's earnings, the stock is trading at a significant discount to its three-year average, representing a compelling opportunity at today's price.
Don't miss this second chance at a potentially lucrative opportunity
Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this.
On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves:
Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $397,573!*
Apple: if you invested $1,000 when we doubled down in 2008, you'd have $39,453!*
Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $697,627!*
Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join Stock Advisor, and there may not be another chance like this anytime soon.
See the 3 stocks »
*Stock Advisor returns as of June 30, 2025
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Citigroup is an advertising partner of Motley Fool Money. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Danny Vena has positions in Alphabet, Amazon, Meta Platforms, Roku, and The Trade Desk. The Motley Fool has positions in and recommends Alphabet, Amazon, Meta Platforms, Roku, and The Trade Desk. The Motley Fool has a disclosure policy.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
19 minutes ago
- Globe and Mail
Tesla Q2 Deliveries Weak But Shares Rise: What's Next for Investors?
Electric vehicle (EV) and tech giant Tesla TSLA released its second-quarter 2025 production and delivery numbers yesterday. It produced 410,244 vehicles, down on a yearly basis. Deliveries totaled 384,122 units (373,728 Model 3/Y and 10,394 Other Models), down 13.4% year over year. The deliveries also fell short of Wall Street's consensus mark of 390,000 units. Despite the miss, shares of Tesla were up roughly 5%, closing the session at $315.65 yesterday. Tesla's EV business is under pressure. In the first quarter of 2025, Tesla attributed weak deliveries to production disruption associated with the Model Y changeover. However, this doesn't hold true for the second quarter as the new Model Y has been ramped up across factories. In fact, Tesla is producing more and building up inventories, which clearly indicates a demand problem. And this demand problem is not industry-wide. While Tesla's sales declined, General Motors ' GM EV sales more than doubled in the second quarter to 46,280 units. China's EV behemoth BYD Co Ltd BYDDY sold 606,993 units, which increased 42.5% year over year. Clearly, Tesla's brand image is not the same as before. The company's aging model lineup and CEO Elon Musk's increasingly polarizing image have been hurting the company's sales amid cut-throat competition. Energy Storage and Charging Remain Bright Spots for TSLA Amid falling EV demand, Tesla's energy and storage business is thriving, thanks to the strong reception of its Megapack and Powerwall products. Last year, deployments soared 113% year over year, driven largely by the expansion efforts at the Mega factory in Lathrop, CA. In the second quarter of 2025, Tesla deployed 9.6 GWh of energy storage, up from 9.4 GWh in the year-ago quarter. The company expects deployments in 2025 to increase another 50% at least. Notably, this segment carries the highest margins across Tesla's business lines. However, being a small contributor to overall revenues, its strength isn't enough to offset the ongoing weakness in the EV segment. Tesla's Supercharger network has also become a critical component of the company's ecosystem. The rollout of the North American Charging Standard has bolstered Tesla's position, allowing various automakers to access its charging Tesla has more than 70,000 Superchargers, making it the largest EV charging network globally. TSLA Investors Pinning Hopes on Robotaxi? Tesla is banking on self-driving technology to drive its next wave of growth. The company recently launched robotaxi services in Austin and completed a fully autonomous Model Y delivery, with no driver and no remote guidance. Musk envisions robotaxis as a game-changing revenue stream amid rising EV competition. But despite the bold push, Tesla trails leaders like Waymo in the autonomous vehicle race. As with many of Tesla's ambitious promises, investors should temper expectations. Regulatory hurdles, safety concerns and the technical complexity of full autonomy remain significant obstacles that could delay large-scale deployment and profitability. Tesla's Price Performance & Valuation Year to date, shares of Tesla have declined 22%, handily underperforming peers like General Motors and BYD. While General Motors' shares lost a modest 1%, BYD gained more than 37% during the same timeframe. YTD Price Performance Comparison Tesla's valuation remains stretched. Going by its price/sales ratio, the company is trading at a forward sales multiple of 9.64, way higher than General Motors and BYD. TSLA's P/S Vs. BYDDY & GM Image Source: Zacks Investment Research This premium is difficult to justify based on fundamentals. The market seems to be pricing in major breakthroughs in high-risk frontiers like autonomous driving and humanoid robotics—bets that are far from guaranteed to pay off. Zacks Estimates for TSLA The Zacks Consensus Estimate for Tesla's 2025 sales and earnings implies a year-over-year decline of 2% and 22%, respectively. The EPS estimate for Tesla has been trending southbound over the past 90 days. How to Play Tesla Now Tesla has been a big winner over the past decade, but its recent performance tells a different story. Delivery shortfalls, margin pressure, and increasing competition are taking a toll. Add to that Musk's controversies with U.S. President Trump, and it's no surprise that investor sentiment is wavering. Downward revisions in earnings estimates and growing volatility paint a challenging near-term outlook. While Tesla still has long-term potential, particularly in areas like energy and autonomy, the risks currently outweigh the rewards. Until Tesla shows real progress on both the tech and execution front, investors may be better off staying on the sidelines—or even locking in any profits if they haven't already. Tesla currently carries a Zacks Rank #5 (Strong Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report General Motors Company (GM): Free Stock Analysis Report Tesla, Inc. (TSLA): Free Stock Analysis Report Byd Co., Ltd. (BYDDY): Free Stock Analysis Report

Globe and Mail
19 minutes ago
- Globe and Mail
Nvidia set to become the world's most valuable company in history
Nvidia (NVDA-Q) was on track to become the most valuable company in history on Thursday, with the chipmaker's market capitalization reaching US$3.92-trillion as Wall Street doubled down on optimism about AI. Shares of the leading designer of high-end AI chips were up 2.2 per cent at US$160.6 in morning trading, giving the company a higher market capitalization than Apple's record closing value of US$3.915-trillion on December 26, 2024. Nvidia's newest chips have made gains in training the largest artificial-intelligence models, fueling demand for products by the Santa Clara, California, tech company. Microsoft (MSFT-Q) is currently the second-most valuable company on Wall Street, with a market capitalization of US$3.7-trillion as its shares rose 1.4 per cent on US$498. Apple (AAPL-Q) rose 0.5 per cent, giving it a stock market value of US$3.19-trillion, in third place. A race among Microsoft, (AMZN-Q), Meta Platforms (META-Q), Alphabet (GOOGL-Q) and Tesla (TSLA-Q) to build AI data centers and dominate the emerging technology has fueled insatiable demand for Nvidia's high-end processors. The stock market value of Nvidia, whose core technology was developed to power video games, has nearly octupled over the past four years from US$500-billion in 2021. Nvidia is now worth more than the combined value of the Canadian and Mexican stock markets, according to LSEG data. The tech company also exceeds the total value of all publicly listed companies in the United Kingdom. Nvidia recently traded at about 32 times analysts' expected earnings for the next 12 months, below its average of about 41 over the past five years, according to LSEG data. That relatively modest price-to-earnings valuation reflects steadily increasing earnings estimates that have outpaced Nvidia's sizable stock gains. The company's stock has now rebounded more than 68 per cent from its recent closing low on April 4, when Wall Street was reeling from President Donald Trump's global tariff announcements. U.S. stocks, including Nvidia, have recovered on expectations that the White House will cement trade deals to soften Trump's tariffs. Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.


Globe and Mail
19 minutes ago
- Globe and Mail
FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug
Regeneron Pharmaceuticals, Inc. REGN obtained FDA approval for linvoseltamab-gcpt for the treatment of relapsed or refractory (R/R) multiple myeloma (MM). The regulatory body granted accelerated approval to linvoseltamab under the brand name Lynozyfic for the treatment of R/R MM who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti CD38 monoclonal antibody. Lynozyfic is a fully human BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on MM cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing. Year to date, REGN's shares have lost 22.9% compared with the industry 's 0.6% decline. More on REGN's MM Drug The approval was based on positive results from the phase I/II LINKER-MM1 trial, wherein Lynozyfic demonstrated one of the highest objective response rates (70%) and complete response rates (45%) among bispecific antibodies for this challenging patient population. With the FDA approval, Lynozyfic is the first FDA-approved BCMAxCD3 bispecific antibody that can be dosed every two weeks starting at week 14, and every four weeks if a very good partial response (VGPR) or better is achieved following completion of at least 24 weeks of therapy. MM remains the second most common blood cancer, with more than 36,000 new cases expected in the US in 2025 alone. Lynozyfic is tailored for patients who have undergone at least four prior treatment regimens, addressing a critical unmet need in late-stage MM. The approval strengthens REGN's oncology portfolio. Lynozyfic is also approved in the European Union to treat adults with R/R MM after at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy. We note that the FDA had earlier issued a CRL for the BLA for linvoseltamab in R/R multiple myeloma. The sole approvability issue identified was related to findings from a pre-approval inspection at a third-party fill/finish manufacturer. REGN's Efforts to Strengthen Oncology Portfolio REGN is currently looking to strengthen its oncology franchise, which currently comprises Libtayo, indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous squamous cell carcinoma and advanced non-small cell lung cancer. REGN's oncology franchise received a boost with the European Commission's approval of odronextamab in 2024 for treating adult patients with R/R follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The drug has been approved under the brand name Ordspono. However, the company's efforts to get odronextamab approved in the United States suffered a setback. The regulatory body issued CRLs for its BLA for odronextamab in 2024. The FDA has accepted for review the resubmission of the BLA for odronextamab in R/R follicular lymphoma with a target action date of July 30, 2025. The successful development of these oncology drugs should be a great boost for REGN. The decline in lead drug Eylea sales is a concern for REGN. Eylea sales are under pressure due to competition from Roche 's RHHBY Vabysmo. Roche designed Vabysmo to block pathways involving Ang-2 and VEGF-A. The uptake of Vabysmo has been outstanding, causing a loss of market share for Eylea. REGN's Zacks Rank and Stocks to Consider REGN currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the pharma/biotech sector are Novartis NVS and Bayer BAYRY, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for Novartis' 2025 earnings per share (EPS) has risen from $8.69 to $8.81 over the past 60 days. EPS estimates for 2026 have jumped 12 cents to $9.12 during this time frame. The stock has risen 30.2% so far this year. BAYRY's 2025 EPS estimate has increased from $1.19 to $1.25 over the past 90 days, while that for 2026 has gone up from $1.28 to $1.31 over the same time frame. Year to date, shares of Bayer have surged 60%. BAYRY's earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report